• Heather A Lillemoe, Guillaume Passot, Yoshikuni Kawaguchi, Mario DeBellis, Olivier Glehen, Yun Shin Chun, TzengChing-Wei DCDDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Cente... more r, Houston, Texas., Thomas A Aloia, Jonathan Lopez, and Jean-Nicolas Vauthey. less
• Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
• Ann. Surg. 2022 Aug 1; 276 (2): 357-362.

ObjectiveTo determine if tumor genetics are associated with overall survival (OS) after concurrent resection of colorectal liver metastases (CLM) and extrahepatic disease (EHD).Summary Background DataThe prognosis for patients who undergo concurrent resection of CLM/EHD is unclear and the impact of somatic mutations has not been reported.MethodsPatients undergoing concurrent resection of CLM and EHD from 2007 to 2017 were identified from 2 academic centers. From 1 center, patients were selected from a pre-existing database of patients undergoing cytore-ductive surgery with hyperthermic intraperitoneal chemotherapy. The Kaplan-Meier method was used to construct survival curves, compared using the log-rank test. Multivariable Cox analysis for OS was performed.ResultsOne hundred nine patients were included. Most common EHD sites included lung (33 patients), peritoneum (32), and portal lymph nodes (14). TP53 mutation was the most common mutation, identified in 75 patients (69%), and RAS/TP53 co-mutation was identified in 31 patients (28%). The median OS was 49 months (interquartile range, 24-125), and 3- and 5-year OS rates were 66% and 44%, respectively. Compared to patients without RAS/ TP53 co-mutation, patients with RAS/TP53 co-mutation had lower median OS: 39 vs. 51 months ( P = 0.02). On multivariable analysis, lung EHD [hazard ratio (HR), 0.7; 95% confidence intervals (CI), 0.3-1.4], peritoneal EHD (HR, 2.2; 95% CI, 1.1-4.2) and RAS/TP53 co-mutation (HR, 2.8; 95% CI, 1.1-7.2) were independently associated with OS.ConclusionsRAS/TP53 co-mutation is associated with worse OS after concurrent CLM/EHD resection. Mutational status and site of EHD should be included in the evaluation of patients considered for concurrent resection.Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

15 keywords...

hide…